Table 1.

CRS and neurotoxicity rates

References	Disease type	CAR construct	Population	CRS	NT	CRS management
Maude et al. [28]	B-ALL	Anti-CD19 CART	N = 75	77% CRS	40% NT	37% Tocilizumab, NR% corticosteroids
		4-1BB	Peds & AYA	46% severe	13% Severe
Gardner et al. [30]	B-ALL	Anti-CD19 CART	N = 45	93% CRS	49% NT	37% Tocilizumab, 23% corticosteroids
		4-1BB	Peds & AYA	23% severe	21% Severe
Park et al. [29]	B-ALL	Anti-CD19 CART	N = 53	85% CRS	62% NT	11% Tocilizumab, 21% corticosteroids
		CD28	Adults	26% severe	42% severe
Schuster et al. [32]	B cell lymphoma	Anti-CD19 CART	N = 93	58% CRS	NR-NT	15% Tocilizumab, 11% corticosteroids
		4-1BB	Adults	23% severe	12% severe
Neelapu et al. [31]	B cell lymphoma	Anti-CD19 CART	N = 108	93% CRS	67% NT	45% Tocilizumab, 29% corticosteroids
		CD28	Adults	23% severe	30% severe
Abramson et al. [33]	B cell lymphoma	Anti-CD19 CART	N = 102	37% CRS	23% NT	17% Tocilizumab, 21% corticosteroids
		4-1BB	Adults	1% severe	13% severe
Zhao et al. [35]	MM	Anti-BCMA CART	N = 57	90% CRS	2% NT	46% Tocilizumab, 11% vasopressor, and 35% supplemental oxygen
		4-1BB	Adults	7% severe	NR-severe
Brudno et al. [36]	MM	Anti-BCMA CART	N = 16	94% CRS	NR-NT	31% Tocilizumab, 25% corticosteroids, 38% vasopressor
		CD28	Adults	38% severe	19% severe
Cohen et al. [37]	MM	Anti-BCMA CART	N = 25	88% CRS	32% NT	28% Tocilizumab, 21% corticosteroids
		4-1BB	Adults	32% severe	12% severe
Raje et al. [38]	MM	Anti-BCMA CART	N = 33	76% CRS	42% NT	21% Tocilizumab, 12% corticosteroids
		4-1BB	Adults	0% severe	3% severe

Different severity grading scales were used.

AYA, adolescent and young adults; Peds, pediatrics.